BriaCell Therapeutics Corp. (NASDAQ: BCTX) reported a median overall survival of 16.6 months for its lead cancer immunotherapy candidate, Bria-IMT, in heavily pretreated metastatic breast cancer patients, threatening to raise the bar in a setting with few effective options. The data, from a Phase 2 study using the formulation now in a pivotal Phase 3 trial, will be presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting.
“These data from the ongoing pivotal Phase 3 Bria-ABC study highlight Bria-IMT’s potential to preserve quality of life, limit toxicity, and potentially support self-administration — benefits that would be clinically meaningful for patients,” Adam M. Brufsky, Professor of Medicine at the University of Pittsburgh School of Medicine, said in a statement.
The final Phase 2 analysis included 32 patients who had received a median of six prior therapies. For patients receiving the formulation selected for the ongoing Phase 3 Bria-ABC study, the median overall survival (OS) was 16.6 months, with a 12-month survival rate of 52 percent. The treatment regimen, which combines the whole-cell vaccine with a checkpoint inhibitor, showed a tolerable safety profile with no treatment-related discontinuations. Blinded data from the current Phase 3 trial also indicated that patients’ quality of life was largely preserved.
The findings are significant for patients with metastatic breast cancer who have exhausted multiple lines of therapy. The study also identified key biomarkers that predict which patients are most likely to benefit. Patients with fewer than five circulating tumor cells (CTCs) at baseline had a median OS of 16.6 months versus 5.5 months for those with more. Similarly, patients who developed a positive immune response, measured by delayed-type hypersensitivity (DTH), survived longer than those who did not (11.9 months vs. 4.7 months). These biomarkers could help select patients for treatment in the future, a key aspect of personalizing cancer therapy.
For investors, the data provides further de-risking of the Bria-IMT program as it progresses through its pivotal Phase 3 trial. BriaCell, which has a market cap of approximately $55 million, is a clinical-stage company, and its valuation is highly dependent on clinical success. While the stock fell 4.12% to $3.70 on the day of the announcement, the detailed survival and biomarker data strengthen the case for Bria-IMT's potential efficacy. The company will formally present the full data at the ASCO meeting in Chicago between May 29 and June 2, with full data from the Bria-ABC trial pending the required number of patient outcomes.
This article is for informational purposes only and does not constitute investment advice.
